{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-017206","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2023-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.665364+00:00","generated_at":"2026-06-15T06:05:56.147158+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ChromaDex Q1 revenue $22.6M (+31% YoY), net loss narrows to $1.9M, raises 2023 outlook","bullets":["Record Q1 net sales $22.6M (+31% YoY); Tru Niagen contributed $17.6M.","Gross margin 59.9%; SG&A as % of sales improved to 34.9% from 47.7%.","Net loss $1.9M ($0.03 EPS) vs $7.7M ($0.11 EPS) in Q1 2022; Adjusted EBITDA loss only $0.1M.","Raised conservative end of 2023 revenue outlook to 12.5% growth; generated $2.8M positive operating cash flow.","Operating expenses reduced $2.8M (-15%) driven by lower legal, share-based comp, and severance costs."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-017206","json":"https://secwatch.observer/filing/0001628280-23-017206.json","markdown":"https://secwatch.observer/filing/0001628280-23-017206.md","text":"https://secwatch.observer/filing/0001628280-23-017206.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023017206/0001628280-23-017206-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023017206/cdxc-20230510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-15T06:05:56.147158+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea4fee626568159a21705b99cce6b469bfdf6b36","claim":"Niagen Bioscience, Inc. reported the three months ended March 31, 2023 results: revenue $22.6 million, net income $1.9 million, EPS $(0.03) per share.","evidence_excerpt":"ChromaDex Corporation Reports First Quarter 2023 Financial Results Record net sales of $22.6 million, with a strong gross margin of 59.9%, lower operating expenses, and a net loss and Adjusted EBITDA loss of only $1.9 million and $0.1 million, respectively, for the three months ended March 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828023017206/0001628280-23-017206-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three months ended March 31, 2023"},{"label":"Revenue","value":"$22.6 million"},{"label":"Net income","value":"$1.9 million"},{"label":"EPS","value":"$(0.03) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}